ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0274

Angiopoietin-Like Protein 4, Apolipoprotein C3 and Lipoprotein Lipase Axis in the Abnormal Lipid Profile of Patients with Rheumatoid Arthritis: Relation to Subclinical Atheromatosis

juan Carlos Quevedo1, Laura de Armás-Rillo2, Antonia de Vera-González3, Laura Cáceres1, Cristina Almeida1, Alejandra González-Delgado3 and Iván Ferraz-Amaro3, 1Hospital Universitario Dr. Negrín, Las Palmas de Gran Canaria, Spain, 2Universidad Europea de Canarias, Santa Cruz De Tenerife, Spain, 3Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain

Meeting: ACR Convergence 2021

Keywords: Carotid Artery Disease, Inflammation, rheumatoid arthritis, Subclinical Cardiovascular Disease

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 6, 2021

Title: RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)

Session Type: Poster Session A

Session Time: 8:30AM-10:30AM

Background/Purpose: Rheumatoid arthritis (RA) is associated with an increase in cardiovascular (CV) risk, attributed, among other factors, to the existence of an abnormal lipid profile. The axis made up of angiopoietin-like protein 4 (ANGPTL4), apolipoprotein C3 (ApoC3) and lipoprotein lipase (LPL) has been associated with cardiovascular mortality in healthy population. However, this axis has not been yet characterized in patients with RA. The objective of this study was to evaluate whether there are differences between RA patients and controls in the serum levels of the molecules of this axis, and to analyze their relationship with the activity of the disease or the markers of systemic inflammation as well as with the subclinical atheromatosis that is present in the disease.

Methods: We performed a cross-sectional study that encompassed 569 individuals; 323 patients with RA and 246 controls. Full lipid profile was assessed including serum levels of ANGPTL4, apoC3 and LPL. Carotid intima-media thickness (cIMT) and carotid plaques were assessed in patients. A multivariable analysis, adjusted for standard CV risk factors, was performed to evaluate if there were differences in this axis between patients and controls, and to study the relationship of this axis with data associated with the disease and the presence of subclinical atheromatosis.

Results: After multivariable analysis, adjusted for CV risk factors and for the changes that the disease produces itself over other lipid profile molecules, patients with RA showed higher levels of ANGPTL4 (beta coef. 295 [95% CI 214-376] ng/ml, p=0.000) and ApoC3 (beta coef. 30 [CI95% 18-41] mg / dl, p=0.000), but lower circulating LPL (beta coef. -172 [CI95% -211-133] ng/ml, p=0.000).

Regarding the data related to the disease, an association was found between ESR and ANGPTL4 (beta coef. -3 [CI95% -6–1] ng/ml, p = 0.02), and C-reactive protein and apoC3 (beta coeff. 0.53 [IC95% 0.12-0.95] mg/dl, p=0.01). Likewise, ESR was positively associated with LPL levels (beta coef. 1 [95% CI 0-3] ng/ml, p=0.03). An association was also found between the use of certain treatments and higher serum levels of LPL (hydroxychloroquine, beta coef. 116 [95% CI 30-202] ng/ml, p=0.008; salazopyrin, beta coef. 143 [95% CI 41 -245] ng/ml, p=0.006 and anti-TNF therapy, beta coefficient 101 [95% CI 33-169] ng / ml, p=0.004).
The ANGPTL4-Apoc3-LPL axis did not show a relationship with the presence of carotid plaque in patients with RA. However, while ApoC3 and LPL levels were not associated with cIMT, ANGPTL4 serum levels showed a positive association with it after multivariate analysis (beta coef. 0.06 [95% CI 0.02-0.09] microns, p=0.000).

Conclusion: RA patients have an abnormal ANGPTL4-Apoc3-LPL axis compared to controls. Certain characteristics of the disease related to inflammation justify this alteration. ANGPTL4 serum levels show an independent and significant positive relationship with IMT in patients with RA.


Disclosures: j. Quevedo, None; L. de Armás-Rillo, None; A. de Vera-González, None; L. Cáceres, None; C. Almeida, None; A. González-Delgado, None; I. Ferraz-Amaro, None.

To cite this abstract in AMA style:

Quevedo j, de Armás-Rillo L, de Vera-González A, Cáceres L, Almeida C, González-Delgado A, Ferraz-Amaro I. Angiopoietin-Like Protein 4, Apolipoprotein C3 and Lipoprotein Lipase Axis in the Abnormal Lipid Profile of Patients with Rheumatoid Arthritis: Relation to Subclinical Atheromatosis [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/angiopoietin-like-protein-4-apolipoprotein-c3-and-lipoprotein-lipase-axis-in-the-abnormal-lipid-profile-of-patients-with-rheumatoid-arthritis-relation-to-subclinical-atheromatosis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/angiopoietin-like-protein-4-apolipoprotein-c3-and-lipoprotein-lipase-axis-in-the-abnormal-lipid-profile-of-patients-with-rheumatoid-arthritis-relation-to-subclinical-atheromatosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology